B6;D2-Tg(Eno2-MFN2*R94Q)L87Ugfm/Orl

Status

Available to order

EMMA IDEM:04781
International strain nameB6;D2-Tg(Eno2-MFN2*R94Q)L87Ugfm/Orl
Alternative nameMitoCharc2
Strain typeTransgenic Strains
Allele/Transgene symbolTg(Eno2-MFN2*R94Q)L87Ugfm
Gene/Transgene symbolTg(Eno2-MFN2*R94Q)L87Ugfm

Information from provider

ProviderRomain Cartoni
Provider affiliationF.M. Kirby Neurobiology Center , Children
Genetic informationThe MitoCharc2 transgene was designed with the human mitofusin 2 (MNF2) gene driven by a neuron specific enolase promoter. Amino acid 94 of MNF2 was mutated from an Arginine (R) to a Glutamine (Q) to mimic the most commonly mutated residue in Charcot-Marie-Tooth disease type 2A (CMT2A). The transgene was microinjected into fertilized C57BL/6 x DBA/2 F1 oocytes, and founder mice were bred to C57BL/6J mice to establish a colony.
Phenotypic informationMitoCharc2 transgenic mice exhibit symptoms of CMT2A including locomotor impairment, gait defects, and a shift in the size of myelinated axons correlating with an increase in mitochondria in these axons at 5 months of age.
Breeding historyFounders with the mixed background C57BL/6 x B6D2F1 were first bred with pure C57BL/6. Transgenic homozygotes were generated by breeding hemizygotes from these litters and maintained by inbred crossing.
References
  • Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A.;Cartoni Romain, Arnaud Estelle, Médard Jean-Jacques, Poirot Olivier, Courvoisier Delphine S, Chrast Roman, Martinou Jean-Claude, ;2010;Brain : a journal of neurology;133;1460-9; 20418531
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedno

Information from EMMA

Archiving centreInstitut de Transgenose, INTRAGENE, Orléans, France
Animals used for archivingheterozygous C57BL/6J, wild-type C57BL/6J

Disease and phenotype information

MGI allele-associated human disease models

MGI phenotypes (allele matching)
  • impaired coordination / MGI
  • abnormal gait / MGI
  • short stride length / MGI
  • abnormal posture / MGI
  • nervous system phenotype / MGI
  • abnormal axon morphology / MGI
  • axon degeneration / MGI
  • tail dragging / MGI
  • increased mitochondria number / MGI
MGI phenotypes (gene matching)
  • impaired coordination / MGI
  • abnormal gait / MGI
  • short stride length / MGI
  • abnormal posture / MGI
  • nervous system phenotype / MGI
  • abnormal axon morphology / MGI
  • axon degeneration / MGI
  • tail dragging / MGI
  • increased mitochondria number / MGI

Literature references

  • Expression of mitofusin 2(R94Q) in a transgenic mouse leads to Charcot-Marie-Tooth neuropathy type 2A.;Cartoni Romain, Arnaud Estelle, Médard Jean-Jacques, Poirot Olivier, Courvoisier Delphine S, Chrast Roman, Martinou Jean-Claude, ;2010;Brain : a journal of neurology;133;1460-9; 20418531

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
For this strain no provider MTA is needed. Distribution is based on the EMMA conditions only.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).